Cellumed Co. Ltd Asset Resilience Ratio
Cellumed Co. Ltd asset resilience ratio. Cellumed Co. Ltd (049180) has an Asset Resilience Ratio of 1.60% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Cellumed Co. Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cellumed Co. Ltd (2008–2024)
Asset resilience ratio of Cellumed Co. Ltd from 2008 to 2024. This chart shows how Cellumed Co. Ltd's Asset Resilience Ratio has changed over time. Read Cellumed Co. Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cellumed Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Cellumed Co. Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩1.14 Billion | 1.6% |
| Total Liquid Assets | ₩1.14 Billion | 1.60% |
Asset Resilience Insights
- Limited Liquidity: Cellumed Co. Ltd maintains only 1.60% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cellumed Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Cellumed Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Autek China Inc
SHE:300595 |
Medical Instruments & Supplies | 21.20% |
|
Pegavision
TW:6491 |
Medical Instruments & Supplies | 17.14% |
|
Crossject
PA:ALCJ |
Medical Instruments & Supplies | 1.31% |
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Nanosonics Ltd
AU:NAN |
Medical Instruments & Supplies | 46.84% |
|
SDI Ltd
AU:SDI |
Medical Instruments & Supplies | 3.36% |
|
Austco Healthcare Ltd
AU:AHC |
Medical Instruments & Supplies | 15.90% |
|
Trajan Group Holdings Ltd
AU:TRJ |
Medical Instruments & Supplies | 0.29% |
Cellumed Co. Ltd Asset Resilience Ratio by Year (2008–2024)
Cellumed Co. Ltd asset resilience ratio by year from 2008 to 2024. The table below shows the annual Asset Resilience Ratio data for Cellumed Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.05% | ₩34.26 Million ≈ $23.22K |
₩70.22 Billion ≈ $47.59 Million |
-0.88pp |
| 2023-12-31 | 0.93% | ₩619.54 Million ≈ $419.85K |
₩66.47 Billion ≈ $45.05 Million |
-9.96pp |
| 2022-12-31 | 10.90% | ₩10.16 Billion ≈ $6.89 Million |
₩93.26 Billion ≈ $63.20 Million |
-15.10pp |
| 2021-12-31 | 25.99% | ₩25.05 Billion ≈ $16.98 Million |
₩96.37 Billion ≈ $65.31 Million |
-6.39pp |
| 2020-12-31 | 32.38% | ₩22.93 Billion ≈ $15.54 Million |
₩70.80 Billion ≈ $47.98 Million |
-0.31pp |
| 2019-12-31 | 32.69% | ₩21.24 Billion ≈ $14.40 Million |
₩64.98 Billion ≈ $44.04 Million |
+16.18pp |
| 2018-12-31 | 16.51% | ₩8.18 Billion ≈ $5.55 Million |
₩49.58 Billion ≈ $33.60 Million |
+13.02pp |
| 2017-12-31 | 3.48% | ₩2.26 Billion ≈ $1.53 Million |
₩64.98 Billion ≈ $44.04 Million |
-5.63pp |
| 2016-12-31 | 9.11% | ₩6.36 Billion ≈ $4.31 Million |
₩69.79 Billion ≈ $47.30 Million |
+5.37pp |
| 2015-12-31 | 3.74% | ₩3.07 Billion ≈ $2.08 Million |
₩82.00 Billion ≈ $55.57 Million |
+2.85pp |
| 2014-12-31 | 0.88% | ₩622.65 Million ≈ $421.96K |
₩70.40 Billion ≈ $47.71 Million |
-0.83pp |
| 2013-12-31 | 1.72% | ₩1.34 Billion ≈ $905.58K |
₩77.78 Billion ≈ $52.71 Million |
+0.71pp |
| 2012-12-31 | 1.01% | ₩835.60 Million ≈ $566.27K |
₩82.59 Billion ≈ $55.97 Million |
-2.32pp |
| 2011-12-31 | 3.33% | ₩2.64 Billion ≈ $1.79 Million |
₩79.25 Billion ≈ $53.70 Million |
+2.97pp |
| 2008-12-31 | 0.37% | ₩230.00 Million ≈ $155.87K |
₩62.32 Billion ≈ $42.23 Million |
-- |
About Cellumed Co. Ltd
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi… Read more